Neuroinflammation in Alzheimer's Disease
By Michael T. Heneka, M. Carson, J. E. Khoury, G. Landreth, F. Brosseron, D. Feinstein, A. Jacobs, T. Wyss‐Coray, J. Vitorica, R. Ransohoff and 27 more. Lancet Neurology, 2015
5,298 citations recorded by the source corpus.
Increasing evidence suggests that Alzheimer's disease pathogenesis is not restricted to the neuronal compartment but strongly interacts with immunological mechanisms in the brain. Misfolded and aggregated proteins bind to pattern recognition receptors on micro- and astroglia and trigger an innate immune response, characterized by the release of inflammatory mediators, which contribute to disease progression and severity. Genome wide analysis suggests that several genes, which increase the risk for sporadic Alzheimer's disease en-code for factors that regulate glial clearance of misfolded proteins and the inflammatory reaction. External factors, including systemic inflammation and obesity are likely to interfere with the immunological processes of the brain and further promote disease progression. This re-view provides an overview on the current knowledge and focuses on the most recent and exciting findings. Modulation of risk factors and intervention with the described immune mechanisms are likely to lead to future preventive or therapeutic strategies for Alzheimer's disease.
Subfields: Clinical Biochemistry, Neurology, Physiology
View Paper: https://www.semanticscholar.org/paper/05b909ab2fc627f66b747cb88b77010b6d3ceaeb
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Clinical Biochemistry
In Neurology
- Michael A. Nitsche
- Alvaro Pascual-Leone
- Agnes Flöel
- Leonardo G. Cohen
- Walter Paulus
- Felipe Fregni
- John C. Rothwell
- Friedhelm Christoph Hummel
In Physiology
Citations in the corpus
- Low intensity transcranial electric stimulation: Safety, ethical, legal regulatory and application guidelines (2017, background): “and Kumar, 2016), as well as in neurodegenerative diseases such as Parkinson’s disease (PD) (Tansey and Goldberg, 2010) and Alzheimer’s disease (AD) (Heneka et al., 2015).”
- The neuropathological diagnosis of Alzheimer’s disease (2019, background): “Microglial cells are phagocytes that operate within the brain, monitoring their territories for pathogen exposure or deteriorating neurons, which promotes their migration to the site and subsequent activation and at times antigen presentation [84, 85].”
- Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. (2017, background): “…mediated by activated microglia, reactive astrocytes and complement activation, that have been especially observed in the vicinity of amyloid plaques and even in the early stages of AD (Heppner et al., 2015; Clark et al., 2015; Heneka et al., 2015; Latta et al., 2015; Stoeck et al., 2014).”
- KOBAS-i: intelligent prioritization and exploratory visualization of biological functions for gene enrichment analysis (2021, result): “Additionally, cluster 4 containing the most terms was related to the immune functions, which was consistent with the finding of strong neuroinflammation in Alzheimer’s disease (45).”
- The blood-brain barrier in Alzheimer's disease (2017, neutral): “Therefore, the brain can no longer be viewed as an immunoprivileged organ and NVU dysfunction should be considered in a broader context, including peripheral immune cells and circulating soluble molecules that mediate immune responses (Heneka et al., 2015; Zenaro et al., 2015).”